Company / Capital Expenditures
Immunovant, Inc. Capital Expenditures History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$759.0K
FY2024
5-year range
$197.0K / $759.0K
FY2020-FY2024
Trend
+110.8%
vs FY2023
Sector context
#121 of 192
Health Care
What the data says
At $759,000, Immunovant, Inc.'s capital expenditures ranks #121 of 192 in the Health Care sector. Capital Expenditures has fluctuated over the past 7 years, ranging from $31,000 in FY2019 to $759,000 in FY2024.
Based on SEC 10-K filings.
$759,000 in FY2024 with a 5-year CAGR of +89.6%.
Improved from $197,000 to $759,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +44.0%
- 5-Year CAGR
- +89.6%
- 10-Year CAGR
- -
Sector benchmark
#121 of 192 in Health CareTop 63% of 192This company $759.0K Sector average $118.6M
▼
-99.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +89.6%, indicating consistent growth.
- In FY2024, capital expenditures increased 110.8% year-over-year.
- Ranks #121 out of 192 companies in the Health Care sector.
- Lowest capital expenditures in the period was in FY2019.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $759.0K | +110.8% |
| FY2023 | $360.0K | +82.7% |
| FY2022 | $197.0K | -22.4% |
| FY2021 | $254.0K | +21.0% |
| FY2020 | $210.0K | +577.4% |
| FY2019 | $31.0K | -40.4% |
| FY2018 | $52.0K | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026